trial

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

NCTId NCT04457310
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 112 (actual)
Sponsored by Yale University
Primary completion 2024-03-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
112 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2021-03-02
Primary completion
2024-03-22
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
CVL-562 (PF-06412562) 1 mgCVL-562 (PF-06412562) 4 mgCVL-562 (PF-06412562) 15 mgCVL-562 (PF-06412562) 25 mg

Sponsors

Yale UniversityLead Sponsor
Columbia UniversityCollaborator
University of PennsylvaniaCollaborator
State University of New York Stony BrookCollaborator
Cerevel Therapeutics, LLCCollaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
John Krystal, MDPrincipal Investigator

Sites

4 total
New Haven, United StatesNew York, United StatesStony Brook, United StatesPhiladelphia, United States

Linked catalysts

1
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Parti — primary completion2024-03-22

Facts & assertions

4 sourced
Enrollment
112
Phase
PHASE2
Primary Completion Date
2024-03-22
Status
COMPLETED
relationships
The graph out of here
drug
CVL-562 (PF-06412562) 1 mg
drug
CVL-562 (PF-06412562) 4 mg
drug
CVL-562 (PF-06412562) 15 mg
drug
CVL-562 (PF-06412562) 25 mg
drug
lead_sponsor
Yale University
company
collaborator
Columbia University
company
University of Pennsylvania
company
indication
Early Course Schizophrenia Spectrum Disorder
indication
investigator
John Krystal, MD
person